Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has successfully secured A$75 million through a two-tranche placement and launched a share purchase plan (SPP) of up to A$5 million to accelerate the commercialisation and expansion of its Salix® software in the U.S. market. The funds will be used to enhance U.S. commercial entry, expand adoption across major hospital groups, and advance clinical studies, reinforcing the company’s position in addressing coronary artery disease. The capital raising reflects strong market confidence in Artrya’s technology and its potential impact on global health challenges.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is a medical technology company focused on the commercialisation of its AI-powered cloud platform, Salix®, which provides near real-time, point-of-care assessment and management of coronary artery disease. The company is primarily targeting the U.S. market following recent FDA clearance of its Salix® Coronary Plaque module.
Average Trading Volume: 478,002
Technical Sentiment Signal: Buy
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.